Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200146 | 0.98 | HRH3 (0.75) | HRH3MEN1KMT2AKCNH2ACHE | |
| SCHEMBL2827364 | 0.98 | HRH3 (0.75) | HRH3MEN1KMT2AKCNH2ACHE | |
| SCHEMBL15834050 | 0.96 | HRH3 (0.67) | HRH3MEN1KMT2AKCNH2ACHE | |
| SCHEMBL13246342 | 0.95 | HRH3 (0.71) | HRH3MEN1KMT2AL3MBTL1MAPK14 | |
| SCHEMBL4089489 | 0.94 | HRH3 (0.84) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL10200144 | 0.93 | MEN1 (0.71) | HRH3MEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL491546 | 0.93 | MEN1 (0.71) | HRH3MEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL13246349 | 0.93 | HRH3 (0.73) | HRH3MEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL5857286 | 0.92 | MEN1 (0.69) | HRH3MEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL12835095 | 0.92 | HRH3 (0.73) | HRH3MEN1KMT2AKCNH2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-1732543-B1 | TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-8940896-B2 | Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS , INC. A CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS , INC. A CORPORATION | 2008-07-31 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007047775-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH3 1072/4885MEN1 1238/4885KMT2A 35/4885 |
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | HRH3 428/4885MEN1 739/4885KMT2A 2214/4885 |
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | HRH3 1/4885MEN1 1263/4885KMT2A 394/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HRH3 629/4885MEN1 1665/4885KMT2A 48/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | HRH3 4225/4885MEN1 4693/4885KMT2A 3947/4885 |
| US-20080182866-A1 | Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, TEK, FLT4 | HRH3 1176/4885MEN1 2698/4885KMT2A 3341/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HRH3 1208/4885MEN1 628/4885KMT2A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.